Biodesix expands its Bio-Rad partnership to validate ddPCR cancer assays, starting with ESR1 mutation testing in breast ...
TipRanks on MSN
Radiopharm Theranostics’ RAD301 Study: A Potential Game-Changer in Cancer Diagnostics
Radiopharm Theranostics Limited (($AU:RAD)) announced an update on their ongoing clinical study. Radiopharm Theranostics Limited is conducting a ...
CEO Jensen Huang doesn’t do PowerPoint presentations. He doesn’t do one-on-one meetings. And if you walk into his office with ...
Testing Market is on the brink of substantial transformation. Projected to grow from USD 640.5 million in 2025 to ...
Hospitals are set to account for 57.3% of global predisposition biomarker revenue in 2025, underscoring their critical role ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results